Esperion Therapeutics (ESPR) investor relations material

Financial performance and growth

• Achieved 38% year-over-year total revenue growth and 34% year-over-year TRx growth, with $408 million in total revenue for the year and 11% TRx growth quarter-over-quarter.

• Strong commercial access with 90% coverage in both commercial and Medicare segments, and stable gross-to-net projections.

• International partnerships are driving growth, with significant contributions from Europe (notably Germany, Belgium, UK, and France) and Japan, where sales exceeded expectations.

• Cash position is strong, ending the year with $168 million and improving, while continuing to deleverage and maintain financial flexibility.

• Confident in sustaining growth rates, with expectations for continued momentum and no end in sight to current growth trajectory.

Strategic acquisition and integration

• Acquired Corstasis for $75 million upfront and up to $180 million in milestone payments, plus low double-digit royalties, with deal expected to close in early April.

• Acquisition brings a unique nasal loop diuretic, Enbumyst, approved in September 2025, targeting heart failure patients resistant to oral diuretics.

• Integration plans include leveraging existing commercial infrastructure, expanding hospital and acute care coverage, and building payer access.

• Global rights to the acquired product open options for expansion in Europe, Asia, and other regions.

• Pre-integration activities underway, with plans to rapidly scale commercialization and awareness post-close.

Commercial strategy and market positioning

• Focused on maximizing the Bempedoic acid franchise (NEXLIZET, NEXLETOL) and integrating Enbumyst into the portfolio.

• Key messages to healthcare providers emphasize CLEAR Outcomes data, risk reduction, and unique benefits for statin-intolerant patients.

• Digital marketing delivers strong ROI, especially in under-covered geographies, and will be further expanded.

• Ongoing evaluation and expansion of field force to support both existing and new products.

• Guidelines expected soon are anticipated to provide a significant tailwind for Bempedoic acid products.